Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Janux Therapeutics (JANX) Shares Outstanding (2020 - 2025)

Historic Shares Outstanding for Janux Therapeutics (JANX) over the last 6 years, with Q3 2025 value amounting to $60.1 million.

  • Janux Therapeutics' Shares Outstanding rose 1487.73% to $60.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $60.1 million, marking a year-over-year increase of 1487.73%. This contributed to the annual value of $59.1 million for FY2024, which is 2770.05% up from last year.
  • Janux Therapeutics' Shares Outstanding amounted to $60.1 million in Q3 2025, which was up 1487.73% from $59.3 million recorded in Q2 2025.
  • Janux Therapeutics' 5-year Shares Outstanding high stood at $60.1 million for Q3 2025, and its period low was $1.2 million during Q1 2021.
  • Moreover, its 5-year median value for Shares Outstanding was $41.9 million (2023), whereas its average is $45.3 million.
  • Its Shares Outstanding has fluctuated over the past 5 years, first surged by 438361.34% in 2021, then soared by 88.25% in 2023.
  • Quarter analysis of 5 years shows Janux Therapeutics' Shares Outstanding stood at $41.2 million in 2021, then increased by 0.9% to $41.6 million in 2022, then increased by 11.14% to $46.3 million in 2023, then rose by 27.7% to $59.1 million in 2024, then rose by 1.79% to $60.1 million in 2025.
  • Its Shares Outstanding stands at $60.1 million for Q3 2025, versus $59.3 million for Q2 2025 and $59.2 million for Q1 2025.